Astrana Health Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Astrana Health Inc (ASTH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Astrana Health Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3,844M vs 452,398M combined for tracked competitors (0.8% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.2% annualized vs trailing 12 months), vs holding steady (-0.4%) for its tracked peer group.
- Growth: Astrana Health Inc generated 48.5% revenue growth year over year in Q2 2026, vs 0.5% for its tracked competitors combined.
- Profitability: Its 1.9% net margin compares with 5.1% for the peer group.
- Scale: Astrana Health Inc ranks #7 of 40 companies by market capitalization in the Consulting Services industry, holding 3.8% of industry market cap.
- Peer revenue share: Astrana Health Inc accounted for 0.9% of combined revenue among its tracked peer group, up from 0.6% a year earlier.
- Peer differentiation: Revenue per employee of $1.28M compares with $1.14M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ASTH Sales vs. its Competitors, Q2 2026
Astrana Health Inc reported revenue growth of 48.52 % year on year in Q2 2026, above its competitors' combined revenue growth of 0.48 %.
With a net margin of 1.90 %, Astrana Health Inc reported lower profitability than its competitors (5.05 %).
Astrana Health Inc generated 0.86 % of the combined sales of its peer group, up from 0.58 % a year earlier.
Astrana Health Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Astrana Health Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Astrana Health Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Astrana Health Inc's competitor groups requires a Commercial License.
For context: the Consulting Services industry grew revenue 7.1% year over year, combined, vs 48.5% for Astrana Health Inc. Astrana Health Inc's share of combined industry revenue moved from 3.37% to 4.68%, a gain of 1.31 percentage points.
Astrana Health Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Astrana Health Inc | Yes | Yes | Yes | Yes |
| Competitors combined (2) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ASTH Stock Performance relative to its Competitors
ASTH Stock Performance relative to High-Confidence Competitors
ASTH Stock Performance relative to Similar-Size Competitors
ASTH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Unitedhealth Group Incorporated | 282.9% | Outperformed |
| 2 | Radnet Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Astrana Health Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Astrana Health Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Astrana Health Inc | 1,721.32 | 3,844.19 |
| Unitedhealth Group Incorporated | 339,722.82 | 450,129.00 |
| Radnet Inc | 5,624.15 | 2,268.93 |
| SUBTOTAL | 347,068.29 | 456,242.12 |
Sources: Astrana Health Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Astrana Health Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Astrana Health Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| RadNet | Named by the company | 85% |
| Envision Healthcare | Named by the company | 85% |
| UnitedHealth Group | Named by the company | 85% |
| Aledade | Named by the company | 85% |
| Heritage California ACO | Named by the company | 85% |
| Optum | Named by the company | 85% |
| P3 Health Partners Inc | Named by the company | 85% |
| California Heart Medical Group | Named by the company | 85% |
| Heritage Provider Network | Named by the company | 85% |
| Regal Medical Group | Named by the company | 85% |
| Foothill Cardiology | Named by the company | 85% |
| Privia Health | Named by the company | 85% |
| DaVita Medical ACO California | Named by the company | 85% |
| Lakeside Medical Group | Named by the company | 85% |
| Time Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Astrana Health Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Astrana Health Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Astrana Health Inc | Care Partners 95.92 % |
| Unitedhealth Group Incorporated | UnitedHealthcare 76.78 % |
| Radnet Inc | Imaging Centers 96.64 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Astrana Health Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Astrana Health Inc | 1,721 | 1,281,397 | 13,074 |
| Unitedhealth Group Incorporated | 339,723 | 1,154,177 | 38,236 |
| Radnet Inc | 5,624 | 288,228 | 2,448 |
| PEERS TOTAL | 345,347 | 1,137,044 | 37,528 |
Astrana Health Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 34 companies in Astrana Health Inc's industry classification, broader than the peer set above. Market cap in millions of $.Astrana Health Inc ranks #7 of 34 companies by market capitalization in its industry, holding 3.84 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,720, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Cgi Inc | 14,393 | 32.07 % |
| 2 | Booz Allen Hamilton Holding Corporation | 8,395 | 18.71 % |
| 3 | Genpact Limited | 5,489 | 12.23 % |
| 4 | Fti Consulting Inc | 3,843 | 8.56 % |
| 5 | Exponent Inc | 1,234 | 5.2% |
| 6 | Huron Consulting Group Inc | 1,234 | 5.2% |
| 7 | Astrana Health Inc | 1,721 | 3.84 % |
| 8 | Icf International Inc | 1,234 | 5.2% |
| 9 | Bowman Consulting Group Ltd | 1,234 | 5.2% |
| 10 | Onterris Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Astrana Health Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-29.
Astrana Health Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 2 | Booz Allen Hamilton Holding Corporation | 8,395 | -29.50 % |
| 3 | Genpact Limited | 5,489 | -23.69 % |
| 4 | Fti Consulting Inc | 3,843 | -18.07 % |
| 5 | Exponent Inc | 3,131 | -8.04 % |
| 6 | Huron Consulting Group Inc | 1,234 | 12.3% |
| 7 | Astrana Health Inc | 1,721 | 16.51 % |
| 8 | Icf International Inc | 1,234 | 12.3% |
| 9 | Bowman Consulting Group Ltd | 1,234 | 12.3% |
| 10 | Onterris Inc | 1,234 | 12.3% |
| 11 | Rmr Group Inc | 1,234 | 12.3% |
| 12 | Tss Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Astrana Health Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-29. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Astrana Health Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Consulting Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (44 companies). See the full Consulting Services industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 10.05 % | 37.97 % (avg) | -27.9 pp |
| Operating Margin | 2.61 % | industry median | +0.5 pp |
| EBITDA Margin | 4.04 % | -0.92 % (avg) | +5.0 pp |
| Capital Intensity (Capex / Revenue) | 0.35 % | 3.90 % (avg) | -3.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Astrana Health Inc's Valuation vs Competitive Position
Valuation multiples vs the Consulting Services industry average (44 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Consulting Services industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 47.8x | 27.6x | +20.2x |
| EV / EBITDA | 16.7x | 10.7x | +6.0x |
| P/B | 2.5x | 2.4x | +0.1x |
| Return on Equity | 4.84 % | industry aggregate | -16.84 % |
| Return on Invested Capital | 3.79 % | 6.13 % (avg) | -2.34 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Astrana Health Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 482.93 % | -14.51 % | 22.58 % | 12.62 % | 47.84 % | 46.72 % | 56.39 % |
| Operating Margin | 8.94 % | 16.83 % | 5.78 % | 11.71 % | 12.69 % | 9.11 % | 4.39 % | 2.47 % |
| Return on Invested Capital | 23.50 % | 18.32 % | 4.41 % | 8.82 % | 8.48 % | 8.10 % | 4.85 % | 3.40 % |
| P/E | - | 31.7x | - | - | - | - | 43.6x | 50.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Astrana Health Inc's Strategic Group Map
Every company in Astrana Health Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Astrana Health Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Astrana Health Inc's BCG Growth-Share Matrix
Relative market share (vs Astrana Health Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Astrana Health Inc falls in the Dog quadrant: relative market share of 0.12x vs its largest competitor, in an industry growing revenue 3.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Astrana Health Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,720 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.35 % vs industry average 3.90 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Astrana Health Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Astrana Health Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Astrana Health Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Astrana Health Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Astrana Health Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 16.8 points below the industry aggregate.
- Low relative market share vs the industry leader (0.12x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Astrana Health Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Astrana Health Inc | 0.65 | 1.34 | 1.25 |
| Unitedhealth Group Incorporated | 0.24 | 0.81 | 0.75 |
| Radnet Inc | 1.10 | 1.61 | 0.86 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Astrana Health Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Astrana Health Inc | Q2 2026 | +48.5 % | +80.6 % |
| Unitedhealth Group Incorporated | Q2 2026 | +0.4 % | +58.7 % |
| Radnet Inc | Q2 2026 | +25.0 % | -12.1 % |
| PEERS TOTAL | +0.8 % | +58.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Astrana Health Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Astrana Health Inc | Q2 2026 | +53.3 % | +173.1 % |
| Unitedhealth Group Incorporated | Q2 2026 | +2.7 % | -9.8 % |
| Radnet Inc | Q2 2026 | - | -16.4 % |
Astrana Health Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Astrana Health Inc | 1.72% | 2.13% | 4.84% |
| Unitedhealth Group Incorporated | 4.78% | 7.51% | 14.55% |
| Radnet Inc | 0.50% | 0.45% | 1.42% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Astrana Health Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Astrana Health Inc | 40.68 | 0.45 |
| Unitedhealth Group Incorporated | 24.13 | 0.75 |
| Radnet Inc | - | 2.48 |
| PEERS AVERAGE | 23.18 | 0.76 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.